- Show all
- Abigail Coursolle
- Alejandra Pavisich
- Alejandra Pavisich
- Alexis Robles-Fradet
- Alicia Emanuel
- Amanda Avery
- Amy Chen
- Andy DiAntonio
- Arielle Linsey
- Brian Brooks
- Candace Gibson
- Carly Myers
- Cassandra LaRose
- Cat Duffy
- Catherine McKee
- Cathren Cohen
- Charlie Blodnieks
- Charly Gilfoil
- Christina Piecora
- Corey Davis
- Dania Douglas
- Daniel Young
- daryln
- David Machledt
- Deanna Hartog
- Elizabeth Edwards
- Elizabeth G. Taylor
- Emma Parker-Newton
- Eskedar Girmash
- Fabiola Carrión
- Georgesula Ziama
- Geron Gadd
- Hannah Eichner
- Hayley Penan
- Héctor Hernández-Delgado
- Ian McDonald
- Jane Perkins
- Jasmine Young
- Jennifer Lav
- Joe McLean
- Kally Xu
- Kasey Nichols
- Kimberly Lewis
- Leonardo Cuello
- lhigashi
- Lisa Munoz
- Liz McCaman Taylor
- Madeline Morcelle
- Mara Youdelman
- Margaret Okakpu
- Maya Levin
- Michelle Lilienfeld
- Michelle Yiu
- Miriam Delaney Heard
- Mizue Suito
- Priscilla Huang
- Rachel Holtzman
- Rolonda Donelson
- Sarah Grusin
- Sarah Somers
- Skyler Rosellini
- Susan Berke Fogel
- T. Nancy Lam
- veng
- Wayne Turner
- Zamir M. Brown
- Show all
- Alabama
- Alaska
- All United States
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- National
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
- July 20, 2020
NHeLP comments on Medicaid Prescrption Drug Rebate Program and Value- based Purchasing Proposed Rulemaking
Read moreIn a proposed rule, CMS seeks to expand value-based purchasing arrangements for prescription drugs in commercial plans and the Medicaid program. However, the proposed changes offer a cost-containment strategy with no safeguards to ensure that Medicaid enrollees can continue to access needed outpatient prescription drugs. NHeLP comments warn against“cost…
- October 11, 2019
NHeLP’s Comments on the Development of a CMS Action Plan to Address the Opioid Epidemic
Read moreIn comments to the Center for Medicare and Medicaid Services (CMS), the National Health Law Program urged the agency to adopt an Action Plan to Prevent Opioid Addiction and Enhance Access to Medication-Assisted Treatment (MAT) that recognizes the inherent value of the Medicaid program as a tool to combat…
- April 3, 2019
Pregnancy, Opioid Use Disorder, and Opioid Agonist Treatment: A Fact Sheet for State-Level Advocates
Read moreThe worsening crisis of opioid-related harm in the U.S. touches all members of society, including pregnant people. People may use opioids during pregnancy for a variety of reasons, including pain management and because they have an opioid use disorder (OUD). Individuals who seek evidence-based care for OUD often experience…